Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_3
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(2)

Detailed Status

Not yet recruiting1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

not_yet_recruiting133%
withdrawn133%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

NCT07149467
terminatedphase_3

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

NCT03517722
withdrawnphase_3

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

NCT04060888

Clinical Trials (3)

Showing 3 of 3 trials
NCT07149467Phase 3

Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

Not Yet Recruiting
NCT03517722Phase 3

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

Terminated
NCT04060888Phase 3

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3